Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRandomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402
Journal of Clinical Oncology, 08/28/09
Lilenbaum R et al. – The prognosis is poor in patients with advanced NSCLC and a PS of 2. Neither docetaxel + cetuximab nor docetaxel + bortezomib met the PFS end point.
Methods- Randomized phase II trial
- 59 patients with advanced NSCLC received docetaxel (30 mg/m2 on d1, 8, and 15 q28 d) in combination with cetuximab (400 mg/m2 load and 250 mg/m2 qw) or bortezomib (1.6 mm2 on d1, 8, and 15 q28d x 4 cycles)
- CR or PR rates were 13.3% and 10.3% for the D + C and D + B groups, respectively
- The median PFS was 3.4 mos in the D + C group and 1.9 mos in the D + B group
- T 6-mos PFS was 27.8% for the D + C group and 21% for the D + B group
- Grade 3/4 hematologic toxicity was 16% for D + C and 21% for D + B, whereas non-hematologic toxicities were 63% and 44%, respectively
Related Articles
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Relevance Score: 71%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 70%
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial
Journal of Clinical Oncology, 11/05/09
Relevance Score: 67%
MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
Medical Oncology, 11/04/09
Relevance Score: 66%
Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
PharmacoEconomics, 10/13/09
Relevance Score: 65%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JRB-10
Journal of Clinical Oncology, 11/30/09
Antiproliferative effect of exemestane in lung cancer cells
Molecular Cancer, 11/30/09
Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study
Journal of Oncology, 11/30/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 11/30/09
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial)
Breast Cancer Research and Treatment, 11/30/09
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
Journal of Clinical Oncology, 11/30/09
Sponsor
Article Search
Sponsor
Sponsor